Zachary J LoVerde1, Lisa A Mandl1, Beverly K Johnson1, Mark P Figgie1, Friedrich Boettner1, Yuo-Yu Lee1, Susan M Goodman2. 1. From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery. 2. From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery. goodmans@hss.edu.
Abstract
OBJECTIVE: More adverse events (AE) are reported after total knee arthroplasty (TKA) for patients with rheumatoid arthritis (RA) than for patients with osteoarthritis (OA). This study evaluates 6-month postoperative AE in a high-volume center in a contemporary RA cohort. METHODS: Patients with RA in an institutional registry (2007-2010) were studied. AE were identified by self-report and review of office and hospital charts. Subjects with RA were matched to 2 with OA by age, sex, and procedure. RA-specific surgical volume was determined. Baseline characteristics and AE were compared and analyzed. RESULTS: There were 159 RA TKA and 318 OA. Of the patients with RA, 88.0% were women, 24.5% received corticosteroids, 41.5% received biologics, and 67% received nonbiologic disease-modifying antirheumatic drugs (DMARD). There was no difference in comorbidities. RA-specific surgical volume was high; 64% of cases were performed by surgeons with ≥ 20 RA cases during the study period. Patients with RA had worse baseline pain and function and lower perceived health status (EQ-5D 0.59 vs 0.65, p < 0.01). There were no deep infections in either group and no difference in superficial infection (9.4% RA vs 10.1% OA, p = 0.82), myocardial infarction (0.7% RA vs 0% OA, p = 0.33), or thromboembolism (1.3% RA vs 0.6% OA, p = 0.60). CONCLUSION: In a high-volume center, with high RA-specific experience, RA does not increase postoperative AE. Despite worse preoperative function and high steroid and DMARD use, complications were not increased. However, further study to determine generalizability is needed.
OBJECTIVE: More adverse events (AE) are reported after total knee arthroplasty (TKA) for patients with rheumatoid arthritis (RA) than for patients with osteoarthritis (OA). This study evaluates 6-month postoperative AE in a high-volume center in a contemporary RA cohort. METHODS:Patients with RA in an institutional registry (2007-2010) were studied. AE were identified by self-report and review of office and hospital charts. Subjects with RA were matched to 2 with OA by age, sex, and procedure. RA-specific surgical volume was determined. Baseline characteristics and AE were compared and analyzed. RESULTS: There were 159 RA TKA and 318 OA. Of the patients with RA, 88.0% were women, 24.5% received corticosteroids, 41.5% received biologics, and 67% received nonbiologic disease-modifying antirheumatic drugs (DMARD). There was no difference in comorbidities. RA-specific surgical volume was high; 64% of cases were performed by surgeons with ≥ 20 RA cases during the study period. Patients with RA had worse baseline pain and function and lower perceived health status (EQ-5D 0.59 vs 0.65, p < 0.01). There were no deep infections in either group and no difference in superficial infection (9.4% RA vs 10.1% OA, p = 0.82), myocardial infarction (0.7% RA vs 0% OA, p = 0.33), or thromboembolism (1.3% RA vs 0.6% OA, p = 0.60). CONCLUSION: In a high-volume center, with high RA-specific experience, RA does not increase postoperative AE. Despite worse preoperative function and high steroid and DMARD use, complications were not increased. However, further study to determine generalizability is needed.
Entities:
Keywords:
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; KNEE; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SURGERY
Authors: Loreto Massardo; Sherine E Gabriel; Cynthia S Crowson; W Michael O'Fallon; Eric L Matteson Journal: J Rheumatol Date: 2002-01 Impact factor: 4.666
Authors: Beverly K Johnson; Susan M Goodman; Michael M Alexiades; Mark P Figgie; Ryan T Demmer; Lisa A Mandl Journal: J Rheumatol Date: 2013-04-01 Impact factor: 4.666
Authors: Bheeshma Ravi; Ruth Croxford; Peter C Austin; Simon Hollands; J Michael Paterson; Earl Bogoch; Hans Kreder; Gillian A Hawker Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Jeffrey N Katz; Jane Barrett; Nizar N Mahomed; John A Baron; R John Wright; Elena Losina Journal: J Bone Joint Surg Am Date: 2004-09 Impact factor: 5.284
Authors: Christina Mertelsmann-Voss; Stephen Lyman; Ting Jung Pan; Susan M Goodman; Mark P Figgie; Lisa A Mandl Journal: Arthritis Rheumatol Date: 2014-06 Impact factor: 10.995
Authors: Jasvinder A Singh; Maria C S Inacio; Robert S Namba; Elizabeth W Paxton Journal: Arthritis Care Res (Hoboken) Date: 2015-05 Impact factor: 4.794
Authors: Elizabeth Salt; Amanda T Wiggins; Mary Kay Rayens; Katelyn Brown; Kate Eckmann; Andrew Johannemann; Raymond D Wright; Leslie J Crofford Journal: J Clin Rheumatol Date: 2018-12 Impact factor: 3.517
Authors: Christopher P Childers; Anaar E Siletz; Emily S Singer; Claire Faltermeier; Q Lina Hu; Clifford Y Ko; Gregory J Golladay; Stephen L Kates; Elizabeth C Wick; Melinda Maggard-Gibbons Journal: Geriatr Orthop Surg Rehabil Date: 2018-02-12
Authors: Yi Ren; Qi Yang; Xisheng Weng; Bin Feng; Tim Luo; Jin Lin; Jin Jin; Wenwei Qian Journal: J Orthop Surg Res Date: 2021-01-27 Impact factor: 2.359